Skip to content
OpenCapital
Get started

Opus Genetics IRD Share-based compensation expense related to employee stock plans

Share-based compensation expense related to employee stock plans at other companies

General Motors logo
General MotorsGM
-$188M-1,989%
Devon Energy logo
Devon EnergyDVN
$22M-26.7%
T-Mobile US logo
T-Mobile USTMUS
$226M+27.7%
PayPal Holdings, Inc. logo
PayPal Holdings, Inc.PYPL
$292M+2.5%
Cadence Design Systems logo
Cadence Design SystemsCDNS
$138.18M+28.4%
Clear Channel Outdoor Holdings, Inc. logo
Clear Channel Outdoor Holdings, Inc.CCO
-6.8%-15.0pp

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M—
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's share-based compensation expense related to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's share-based compensation expense related to employee stock plans?
Opus Genetics (IRD) reported share-based compensation expense related to employee stock plans of $1.46M in Q1 2026.
How has Opus Genetics's share-based compensation expense related to employee stock plans changed year-over-year?
Opus Genetics's share-based compensation expense related to employee stock plans increased by 60.4% year-over-year, from $913K to $1.46M.
What is the long-term trend for Opus Genetics's share-based compensation expense related to employee stock plans?
Over 4 years (2021 to 2025), Opus Genetics's share-based compensation expense related to employee stock plans has grown at a 15.4% compound annual growth rate (CAGR), from $1.91M to $3.4M.